How have GNFT shares performed in 2024?

Genfit's stock was trading at €3.54 at the beginning of 2024. Since then, GNFT shares have decreased by 10.0% and is now trading at €3.19. View the best growth stocks for 2024 here .

What other stocks do shareholders of Genfit own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Alimentation Couche-Tard (ATD.B) , Aecon Group (ARE) , Algonquin Power & Utilities (AQN) , Aptiv (APTV) , American Tower (AMT) , Advanced Micro Devices (AMD) , Ambarella (AMBA) , Albemarle (ALB) , Adobe (ADBE) and Abbott Laboratories (ABT) .

EPA:GNFT

Genfit (GNFT) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free GNFT Stock Alerts

€3.18

+0.01 (+0.31%)

(As of 04/18/2024 ET)

Compare

Today's Range: €3.16
▼
€3.21
50-Day Range: €3.14
▼
€3.58
52-Week Range: N/A

Volume: 41,398 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Headlines

Get Genfit alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Genfit Stock (EPA:GNFT)

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

GNFT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNFT Stock News Headlines

April 8, 2024 | markets.businessinsider.com

Buy Rating Reiterated for Genfit SA Amidst Promising Clinical Developments and Strong Financial Outlook

April 5, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 5, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Genfit SA (GNFT) and Laboratory (LH)

February 15, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading

February 14, 2024 | markets.businessinsider.com

Genfit (GNFTF) Gets a Buy from Kepler Capital

January 20, 2024 | finance.yahoo.com

Genfit S.A. (GNFT.PA)

January 15, 2024 | finance.yahoo.com

GENFIT Announces 2024 Financial Calendar

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

December 11, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Genfit SA Amid Favorable Regulatory Developments and Positive Trial Results

December 6, 2023 | finance.yahoo.com

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

November 16, 2023 | finance.yahoo.com

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

November 13, 2023 | msn.com

Genfit stock rallies 20% after hours on data for liver disease drug

November 12, 2023 | markets.businessinsider.com

Kepler Capital Sticks to Its Buy Rating for Genfit (GNFTF)

November 10, 2023 | finanznachrichten.de

GENFIT S.A.: GENFIT Reports Third Quarter 2023 Financial Information

November 2, 2023 | finance.yahoo.com

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

November 1, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

August 14, 2023 | msn.com

UBS starts Cymabay at buy, expecting positive Phase 3 data for seladelpar

August 11, 2023 | finance.yahoo.com

GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

July 3, 2023 | markets.businessinsider.com

Analyst Expectations for Genfit's Future

June 30, 2023 | msn.com

Genfit gains as Phase 3 trial for liver disease candidate succeeds (update)

June 30, 2023 | markets.businessinsider.com

Ipsen, GENFIT Reveal Positive Phase III Trial Results Of Elafibranor In Patients With PBC

June 4, 2023 | msn.com

Genfit (EPA:GNFT) Price Target Decreased by 11.94% to 8.02

May 24, 2023 | finance.yahoo.com

GENFIT: May 24, 2023 Combined Shareholders Meeting results

May 12, 2023 | finanznachrichten.de

GENFIT S.A.: GENFIT Reports First Quarter 2023 Financial Information

May 11, 2023 | msn.com

Genfit: Major Data Release Before End Of Q2 Of 2023 Could Get Ball Rolling

May 11, 2023 | finance.yahoo.com

GENFIT Reports First Quarter 2023 Financial Information

See More Headlines

Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: EPA
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: EPA:GNFT
CUSIP: N/A
CIK: N/A
Web: www.genfit.com
Phone: 33 3 20 16 40 00
Fax: N/A
Employees: 154
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Jean-Francois Mouney (Age 69)
Co-Founder & Chairman of the Board
Comp: $368.55k
Mr. M. Pascal Prigent (Age 56)
Chief Executive Officer
Comp: $558.54k
Prof. Bart Staels (Age 61)
Co-Founder & Chairman of the Scientific Advisory Board
Mr. Thomas Baetz (Age 50)
Chief Financial Officer
Mr. Pascal Caisey (Age 56)
Chief Operating Officer
Dr. Meriam Kabbaj Ph.D. (Age 50)
Chief Technology Officer
Dr. Dean W. Hum Ph.D. (Age 62)
Chief Scientific Officer
Comp: $710.72k
Mr. Jean-Christophe Marcoux (Age 46)
Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
Mr. Laurent Lannoo (Age 54)
Corporate Secretary & Director of Legal Affairs
Ms. Stefanie Magner J.D. (Age 43)
Chief Compliance Officer & Executive VP of International Legal Affairs

Key Competitors

View All Competitors

GNFT Stock Analysis - Frequently Asked Questions

How have GNFT shares performed in 2024?: Genfit's stock was trading at €3.54 at the beginning of 2024. Since then, GNFT shares have decreased by 10.0% and is now trading at €3.19.
View the best growth stocks for 2024 here.
What other stocks do shareholders of Genfit own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Alimentation Couche-Tard (ATD.B), Aecon Group (ARE), Algonquin Power & Utilities (AQN), Aptiv (APTV), American Tower (AMT), Advanced Micro Devices (AMD), Ambarella (AMBA), Albemarle (ALB), Adobe (ADBE) and Abbott Laboratories (ABT).

This page (EPA:GNFT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Genfit (GNFT) Stock Price, News & Analysis

About Genfit Stock (EPA:GNFT)

GNFT Stock Price History

GNFT Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

GNFT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info